Vivos Therapeutics (NASDAQ:VVOS) Inc has announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.
The medical technology company said study participants with moderate to severe obstructive sleep apnea (OSA) will be randomly assigned to treatment with either Vivos’ DNA appliance or CPAP (continuous positive airway pressure), the current industry standard for OSA treatment.
"I am confident that our technology will bear the scrutiny of a well-designed, prospective clinical trial," Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman said in a statement.
"Our treatment is comfortable, safe and non-invasive, and we believe that at the end of this study, the conclusion will be that Vivos should become an essential part of every OSA care plan," he added.
Vivos noted the protocol has been finalized and participant enrollment will begin in early 2024.
The DNA appliance recently received 510(k) clearance by the FDA for the treatment of mild-to-moderate OSA in adults and represents an entirely novel modality of treatment for a disease that is estimated to afflict one in four adults in the US, according to the company.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults.
Contact Sean at sean@proactiveinvestors.com